1887

Abstract

. The possibility of reinfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a widely proven fact and may have clinical implications.

. It is not known whether there have been cases of reinfection by SARS-CoV-2 in La Ribera Health Department.

To determine whether there have been cases of reinfection by SARS-CoV-2 in La Ribera Health Department and to identify their characteristics.

. Retrospective cross-sectional observational study of cases of reinfection by SARS-CoV-2 in the population of La Ribera Department between March 2020 and February 2021. The positive baseline cohort includes all cases positive by RT-PCR for SARS-CoV-2, with reinfection cases being those that, after resolution of the first episode according to the World Health Organization (WHO) criteria, presented a new positive RT-PCR result.

. Out of a total of 15 687 cases with positive RT-PCR, 40 were considered to be reinfections, which meant a cumulative incidence of 0.255 % and an incidence density of 5.05 cases per 100 000 person-days. Most of the cases occurred during the highest incidence peaks of the pandemic in the department. Seventy-five per cent of the patients in these cases were older than 40 years, 42.5 % were healthcare professionals or nursing home residents and 12.5 % had an immunosuppressive comorbidity. There were no severe, critical or death cases. In the reinfection episodes, with respect to the first episode, there was a tendency to be milder, they required fewer days of hospitalization, their RT-PCR became negative earlier, they developed a greater humoral response and the sick leave period was shorter. The median period between the RT-PCR in the first episode and the RT-PCR in the second episode was 127.5 days (range: 48–301; IQR: 89.5–256.25)

. SARS-CoV-2 reinfection cases are rare, tend to be mild and can occur within a median period of 127.5 days.

Keyword(s): COVID-19 , reinfection and SARS-CoV-2
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. The Microbiology Society waived the open access fees for this article.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001599
2022-10-27
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/71/10/jmm001599.html?itemId=/content/journal/jmm/10.1099/jmm.0.001599&mimeType=html&fmt=ahah

References

  1. Piri SM, Edalatfar M, Shool S, Jalalian MN, Tavakolpour S. A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. Infect Dis 2021; 53:315–324 [View Article]
    [Google Scholar]
  2. Azam M, Sulistiana R, Ratnawati M, Fibriana AI, Bahrudin U et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep 2020; 10:20692 [View Article]
    [Google Scholar]
  3. Gousseff M, Penot P, Gallay L, Batisse D, Benech N et al. Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?. J Infect 2020; 81:816–846 [View Article]
    [Google Scholar]
  4. Gidari A, Nofri M, Saccarelli L, Bastianelli S, Sabbatini S et al. Is recurrence possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of literature. Eur J Clin Microbiol Infect Dis 2021; 40:1–12 [View Article]
    [Google Scholar]
  5. Deng W, Bao L, Liu J, Xiao C, Liu J et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 2020; 369:818–823 [View Article]
    [Google Scholar]
  6. To KK, Hung IF, Ip JD, Chu AW, Chan WM et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis 2020ciaa1275 [View Article]
    [Google Scholar]
  7. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis 2021; 21:52–58 [View Article] [PubMed]
    [Google Scholar]
  8. Goldman JD, Wang K, Roltgen K, Nielsen SCA, Roach JC et al. Reinfection with SARS-CoV-2 and failure of humoral immunity: a case report. medRxiv 20202020.09.22.20192443 [View Article]
    [Google Scholar]
  9. Abu Raddad LJ, Chemaitelly H, Malek JA, Ahmed AA, Mohamoud YA et al. Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting. Clin Infect Dis 2020 [View Article]
    [Google Scholar]
  10. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet 2021; 397:1459–1469 [View Article]
    [Google Scholar]
  11. Adrielle Dos Santos L, Filho PG de G, Silva AMF, Santos JVG, Santos DS et al. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. J Infect 2021; 82:399–406 [View Article]
    [Google Scholar]
  12. Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med 2021; 384:533–540 [View Article]
    [Google Scholar]
  13. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet 2021; 397:1204–1212 [View Article]
    [Google Scholar]
  14. Tomassini S, Kotecha D, Bird PW, Folwell A, Biju S et al. Setting the criteria for SARS-CoV-2 reinfection - six possible cases. J Infect 2021; 82:282–327 [View Article]
    [Google Scholar]
  15. Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect 2021; 27:315–318 [View Article]
    [Google Scholar]
  16. Lechien JR, Chiesa-Estomba CM, Radulesco T, Michel J, Vaira LA et al. Clinical features of patients who had two COVID-19 episodes: a European multicentre case series. J Intern Med 2021; 290:421–429 [View Article]
    [Google Scholar]
  17. Brouqui P, Colson P, Melenotte C, Houhamdi L, Bedotto M et al. COVID-19 re-infection. Eur J Clin Invest 2021; 51:e13537 [View Article]
    [Google Scholar]
  18. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife 2020; 9:e61312 [View Article]
    [Google Scholar]
  19. Hunsinger DHP, Kutti Sridharan DG, Rokkam DVRP, Fantry DLE. COVID-19 Reinfection in an immunosuppressed patient without an antibody response. Am J Med Sci 2021; 362:103 [View Article]
    [Google Scholar]
  20. Seow J, Graham C, Merrick B, Acors S, Pickering S et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 2020; 5:1598–1607 [View Article]
    [Google Scholar]
  21. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371:eabf4063 [View Article]
    [Google Scholar]
  22. Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 2021; 184:476–488 [View Article]
    [Google Scholar]
  23. Cohen JI, Burbelo PD. Reinfection with SARS-CoV-2: Implications for Vaccines. Clin Infect Dis 2021; 73:e4223–e4228 [View Article]
    [Google Scholar]
  24. World Health Organization COVID-19 Clincal managment; 2021 https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1
  25. Graham NSN, Junghans C, McLaren R, Randell P, Lang N et al. High rates of SARS-CoV-2 seropositivity in nursing home residents. J Infect 2021; 82:282–327 [View Article]
    [Google Scholar]
  26. Bentivegna E, Sentimentale A, Luciani M, Speranza ML, Guerritore L et al. New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient. J Med Virol 2021; 93:97–98 [View Article]
    [Google Scholar]
  27. Guallar MP, Meiriño R, Donat-Vargas C, Corral O, Jouvé N et al. Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity. Int J Infect Dis 2020; 97:290–292 [View Article] [PubMed]
    [Google Scholar]
  28. Larson D, Brodniak SL, Voegtly LJ, Cer RZ, Glang LA et al. A case of early re-infection with SARS-cov-2. Clin Infect Dis 2020ciaa1436 [View Article]
    [Google Scholar]
  29. Khoshkam Z, Aftabi Y, Stenvinkel P, Paige Lawrence B, Rezaei MH et al. Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. J Adv Res 2021; 31:49–60 [View Article]
    [Google Scholar]
  30. Shen X, Tang H, Pajon R, Smith G, Glenn GM et al. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. N Engl J Med 2021; 384:2352–2354 [View Article]
    [Google Scholar]
  31. Gulati K, Prendecki M, Clarke C, Willicombe M, McAdoo S. COVID-19 reinfection in a patient receiving immunosuppressive treatment for antineutrophil cytoplasmic antibody-associated vasculitis reinfection in a patient receiving immunosuppressive treatment for antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2021; 73:1091–1092 [View Article]
    [Google Scholar]
  32. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–2615 [View Article]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001599
Loading
/content/journal/jmm/10.1099/jmm.0.001599
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error